National trends in prescription drug expenditures and projections for 2017

2017 ◽  
Vol 74 (15) ◽  
pp. 1158-1173 ◽  
Author(s):  
Glen T. Schumock ◽  
Edward C. Li ◽  
Michelle D. Wiest ◽  
Katie J. Suda ◽  
JoAnn Stubbings ◽  
...  
2014 ◽  
Vol 71 (6) ◽  
pp. 482-499 ◽  
Author(s):  
Glen T. Schumock ◽  
Edward C. Li ◽  
Katie J. Suda ◽  
Linda M. Matusiak ◽  
Robert J. Hunkler ◽  
...  

2016 ◽  
Vol 73 (14) ◽  
pp. 1058-1075 ◽  
Author(s):  
Glen T. Schumock ◽  
Edward C. Li ◽  
Katie J. Suda ◽  
Michelle D. Wiest ◽  
JoAnn Stubbings ◽  
...  

2015 ◽  
Vol 72 (9) ◽  
pp. 717-736 ◽  
Author(s):  
Glen T. Schumock ◽  
Edward C. Li ◽  
Katie J. Suda ◽  
Michelle D. Wiest ◽  
Joann Stubbings ◽  
...  

2018 ◽  
Vol 75 (14) ◽  
pp. 1023-1038 ◽  
Author(s):  
Glen T. Schumock ◽  
JoAnn Stubbings ◽  
Michelle D. Wiest ◽  
Edward C. Li ◽  
Katie J. Suda ◽  
...  

2020 ◽  
Vol 77 (15) ◽  
pp. 1213-1230 ◽  
Author(s):  
Eric M Tichy ◽  
Glen T Schumock ◽  
James M Hoffman ◽  
Katie J Suda ◽  
Matthew H Rim ◽  
...  

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2020 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2020 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for specialty drugs, biosimilars, and diabetes medications. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2020 were based on a combination of quantitative analyses and expert opinion. Results In 2019, overall US pharmaceutical expenditures grew 5.4% compared to 2018, for a total of $507.9 billion. This increase was driven to similar degrees by prices, utilization, and new drugs. Adalimumab was the top drug in US expenditures in 2019, followed by apixaban and insulin glargine. Drug expenditures were $36.9 billion (a 1.5% increase from 2018) and $90.3 billion (an 11.8% increase from 2018) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals growth was driven by new products and price increases. Several new drugs that will likely influence spending are expected to be approved in 2020. Specialty and cancer drugs will continue to drive expenditures. Conclusion For 2020 we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 9.0% to 11.0% and 2.0% to 4.0%, respectively, compared to 2019. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.


2016 ◽  
Vol 57 (4) ◽  
pp. 1016 ◽  
Author(s):  
Jeong-Sook Jo ◽  
Young-Man Kim ◽  
Kyung Won Paek ◽  
Min Hee Bea ◽  
Kihong Chun ◽  
...  

1999 ◽  
Vol 21 (7) ◽  
pp. 1241-1253 ◽  
Author(s):  
Dong-Churl Suh ◽  
Clifton R Lacy ◽  
Joseph A. Barone ◽  
Deana Moylan ◽  
John B. Kostis

2006 ◽  
Vol 28 (4) ◽  
pp. 427-453 ◽  
Author(s):  
Wenhui Wei ◽  
Ayse Akincigil ◽  
Stephen Crystal ◽  
Usha Sambamoorthi

Sign in / Sign up

Export Citation Format

Share Document